Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Phillips GS, et al. Among authors: pabani a. J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216228 Free PMC article.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, Goutam S, Navani V, Heng DYC, Cheung WY, Morris DG, Pabani A. Meyers DE, et al. Among authors: pabani a. JTO Clin Res Rep. 2023 Feb 24;4(4):100482. doi: 10.1016/j.jtocrr.2023.100482. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37090101 Free PMC article.
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers.
O'Sullivan DE, Jarada TN, Yusuf A, Hu LXY, Gogna P, Brenner DR, Abbie E, Rose JB, Eaton K, Elia-Pacitti J, Ewara EM, Pabani A, Cheung WY, Boyne DJ. O'Sullivan DE, et al. Among authors: pabani a. Curr Oncol. 2022 Sep 30;29(10):7198-7208. doi: 10.3390/curroncol29100567. Curr Oncol. 2022. PMID: 36290844 Free PMC article.
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, Rizvi NA. Shu CA, et al. Among authors: pabani a. Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7. Lancet Oncol. 2020. PMID: 32386568 Clinical Trial.
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, Pabani A, Cheung WY, Heng DYC, Cheng T, Monzon JG, Navani V. Watson AS, et al. Among authors: pabani a. JAMA Netw Open. 2022 Dec 1;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596. JAMA Netw Open. 2022. PMID: 36480204 Free PMC article.
25 results